Sarepta Therapeutics (NASDAQ:SRPT) Given Neutral Rating at The Goldman Sachs Group

The Goldman Sachs Group reissued their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report released on Tuesday,Benzinga reports. They currently have a $29.00 price objective on the biotechnology company’s stock.

Other equities research analysts also recently issued research reports about the company. Piper Sandler downgraded Sarepta Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $70.00 to $36.00 in a research report on Monday. Barclays dropped their price objective on Sarepta Therapeutics from $89.00 to $29.00 and set an “overweight” rating on the stock in a report on Tuesday. UBS Group cut their target price on Sarepta Therapeutics from $188.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Wolfe Research started coverage on Sarepta Therapeutics in a research report on Tuesday. They set a “peer perform” rating on the stock. Finally, HC Wainwright downgraded shares of Sarepta Therapeutics from a “neutral” rating to a “sell” rating in a report on Monday. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $74.13.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $21.56 on Tuesday. The firm has a market capitalization of $2.12 billion, a PE ratio of -8.01 and a beta of 0.61. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00. The company has a 50-day moving average price of $45.00 and a two-hundred day moving average price of $84.80. Sarepta Therapeutics has a twelve month low of $18.30 and a twelve month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The business had revenue of $744.86 million for the quarter, compared to analysts’ expectations of $685.75 million. During the same quarter in the previous year, the company posted $0.73 earnings per share. The business’s quarterly revenue was up 80.2% compared to the same quarter last year. Equities analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in SRPT. Byrne Asset Management LLC bought a new stake in Sarepta Therapeutics during the first quarter worth about $30,000. Center for Financial Planning Inc. purchased a new position in shares of Sarepta Therapeutics during the 1st quarter valued at about $31,000. Ancora Advisors LLC lifted its position in Sarepta Therapeutics by 150.0% in the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after buying an additional 300 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its position in Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after buying an additional 194 shares during the last quarter. Finally, Banque Transatlantique SA purchased a new stake in Sarepta Therapeutics in the first quarter worth approximately $44,000. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.